Profiel
Samuel Reed currently works at DNAe Group Holdings Ltd., as Chief Executive Officer & Director.
Actieve functies van Samuel Reed
Bedrijven | Functie | Begin |
---|---|---|
DNAe Group Holdings Ltd.
DNAe Group Holdings Ltd. Medical SpecialtiesHealth Technology Part of Genting Bhd., DNAe Group Holdings Ltd. is a healthcare company based in London, UK. DNAe is commercializing its pioneering semiconductor sequencing technology for healthcare applications, including infectious disease and cancer testing and monitoring. The British company is developing Lidia-seq™, a user-friendly, direct-from-specimen platform that performs genomic analysis on a microchip, to provide actionable information to clinicians. DNAe's initial focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. The company's major shareholder is Genting Berhad, a Malaysian-based investor with a growing portfolio of investments in cutting-edge life sciences companies. The company was founded in 2003 by Christofer Toumazou. The CEO is Samuel Reed. | Algemeen Directeur | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
DNAe Group Holdings Ltd.
DNAe Group Holdings Ltd. Medical SpecialtiesHealth Technology Part of Genting Bhd., DNAe Group Holdings Ltd. is a healthcare company based in London, UK. DNAe is commercializing its pioneering semiconductor sequencing technology for healthcare applications, including infectious disease and cancer testing and monitoring. The British company is developing Lidia-seq™, a user-friendly, direct-from-specimen platform that performs genomic analysis on a microchip, to provide actionable information to clinicians. DNAe's initial focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. The company's major shareholder is Genting Berhad, a Malaysian-based investor with a growing portfolio of investments in cutting-edge life sciences companies. The company was founded in 2003 by Christofer Toumazou. The CEO is Samuel Reed. | Health Technology |